CDK5 and clear cell renal carcinoma: Notably, PPAR-alpha has been identified as a possible therapeutic target for the treatment of clear cell renal cell carcinoma (ccRCC)28, a cancer type that is molecularly and morphologically similar to OCCC29 and one in which CDK5 signaling has also been identified as an important regulatory pathway29.